ONE-WAYOngoing theme · still written in the latest filings
Drug Repositioning of YS-1301, an Inducer of Endogenous Regenerative Factors
A drug repositioning development program using the oxime derivative YS-1301, covering efficacy validation, formulation development, academic collaborations, and out-licensing discussions for multiple diseases, including liver and intestinal diseases.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2023 →Still being written about.
Directionhelps1 helps · 0 hurts · 0 flat